| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
34,075 |
31,399 |
$2.34M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
26,886 |
24,948 |
$1.27M |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
20,484 |
19,142 |
$530K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
54,159 |
50,140 |
$465K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
36,506 |
17,001 |
$363K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
18,067 |
16,943 |
$221K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
19,222 |
17,637 |
$195K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,549 |
1,410 |
$99K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,453 |
1,388 |
$46K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
682 |
647 |
$22K |
| 99051 |
|
806 |
768 |
$13K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
11,097 |
10,277 |
$12K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
9,579 |
8,822 |
$4K |
| 86308 |
|
407 |
382 |
$2K |
| 81002 |
|
661 |
627 |
$2K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
170 |
164 |
$1K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
900 |
828 |
$1K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
51 |
50 |
$1K |
| 71046 |
Radiologic examination, chest; 2 views |
30 |
28 |
$587.10 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
14 |
13 |
$552.70 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
69 |
69 |
$446.40 |
| 82948 |
|
86 |
75 |
$228.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
30 |
29 |
$5.22 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
41 |
40 |
$0.24 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
105 |
103 |
$0.04 |
| 36416 |
|
100 |
92 |
$0.00 |